Ant Pharmacueticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 24-10-2024
- Paid Up Capital ₹ 0.31 M
as on 24-10-2024
- Company Age 8 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.39 Cr
as on 24-10-2024
- Revenue -52.22%
(FY 2023)
- Profit -40.19%
(FY 2023)
- Ebitda -41.78%
(FY 2023)
- Net Worth 4.70%
(FY 2023)
- Total Assets -10.19%
(FY 2023)
About Ant Pharmacueticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.31 M.
The company currently has active open charges totaling ₹2.39 Cr.
Tripti Goel and Basant Goel serve as directors at the Company.
- CIN/LLPIN
U51909MH2016PTC287985
- Company No.
287985
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Nov 2016
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Raigarh, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Ant Pharmacueticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Tripti Goel  | Director | 28-Nov-2016 | Current |
| Basant Goel | Director | 28-Nov-2016 | Current |
Financial Performance of Ant Pharmacueticals.
Ant Pharmacueticals Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 52.22% decrease. The company also saw a substantial fall in profitability, with a 40.19% decrease in profit. The company's net worth moved up by a moderate rise of 4.7%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ant Pharmacueticals?
In 2023, Ant Pharmacueticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Sparshmart Pharmaceuticals Private LimitedActive 17 years 8 monthsTripti Goel and Basant Goel are mutual person
Charges (Loans)
₹23.86 M
₹0
Charges Breakdown by Lending Institutions
- Others : 2.39 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 10 Jul 2020 | Others | ₹3.86 M | Open |
| 07 Jun 2017 | Others | ₹2.00 Cr | Open |
How Many Employees Work at Ant Pharmacueticals?
Unlock and access historical data on people associated with Ant Pharmacueticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ant Pharmacueticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ant Pharmacueticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.